Anti-ST8SIA5 monoclonal antibody

Pre-made anti-ST8SIA5 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to ST8SIA5/ST8SIA5 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP1837-Ab-1/ GM-Tg-hg-IP1837-Ab-2Anti-Human ST8SIA5 monoclonal antibodyHuman
GM-Tg-rg-IP1837-Ab-1/ GM-Tg-rg-IP1837-Ab-2Anti-Rat ST8SIA5 monoclonal antibodyRat
GM-Tg-mg-IP1837-Ab-1/ GM-Tg-mg-IP1837-Ab-2Anti-Mouse ST8SIA5 monoclonal antibodyMouse
GM-Tg-cynog-IP1837-Ab-1/ GM-Tg-cynog-IP1837-Ab-2Anti-Cynomolgus/ Rhesus macaque ST8SIA5 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP1837-Ab-1/ GM-Tg-felg-IP1837-Ab-2Anti-Feline ST8SIA5 monoclonal antibodyFeline
GM-Tg-cang-IP1837-Ab-1/ GM-Tg-cang-IP1837-Ab-2Anti-Canine ST8SIA5 monoclonal antibodyCanine
GM-Tg-bovg-IP1837-Ab-1/ GM-Tg-bovg-IP1837-Ab-2Anti-Bovine ST8SIA5 monoclonal antibodyBovine
GM-Tg-equg-IP1837-Ab-1/ GM-Tg-equg-IP1837-Ab-2Anti-Equine ST8SIA5 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP1837-Ab-1/ GM-Tg-hg-IP1837-Ab-2; GM-Tg-rg-IP1837-Ab-1/ GM-Tg-rg-IP1837-Ab-2;
GM-Tg-mg-IP1837-Ab-1/ GM-Tg-mg-IP1837-Ab-2; GM-Tg-cynog-IP1837-Ab-1/ GM-Tg-cynog-IP1837-Ab-2;
GM-Tg-felg-IP1837-Ab-1/ GM-Tg-felg-IP1837-Ab-2; GM-Tg-cang-IP1837-Ab-1/ GM-Tg-cang-IP1837-Ab-2;
GM-Tg-bovg-IP1837-Ab-1/ GM-Tg-bovg-IP1837-Ab-2; GM-Tg-equg-IP1837-Ab-1/ GM-Tg-equg-IP1837-Ab-2
Products NameAnti-ST8SIA5 monoclonal antibody
Formatmab
Target NameST8SIA5
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-ST8SIA5 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP1837-Ag-1Recombinant multi-species SIA8E/ ST8SIA5/ SIAT8-E protein


    Target information

    Target IDGM-IP1837
    Target NameST8SIA5
    Gene ID29906,225742,364901,696611,100036755,101085668,497020,100068868
    Gene Symbol and SynonymsSATV,SIAT8-E,SIAT8E,ST8SIA5,ST8SiaV
    Uniprot AccessionO15466,Q6ZXC8
    Uniprot Entry NameSIA8E_HUMAN,SIA8E_RAT
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000101638
    Target ClassificationN/A

    The target: ST8SIA5, gene name: ST8SIA5, also named as SIAT8-E, SIAT8E, ST8SiaV. The protein encoded by this gene is a type II membrane protein that may be present in the Golgi apparatus. The encoded protein, which is a member of glycosyltransferase family 29, may be involved in the synthesis of gangliosides GD1c, GT1a, GQ1b, and GT3 from GD1a, GT1b, GM1b, and GD3, respectively. [provided by RefSeq, Jul 2008].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.